Form 4: NeuroPace CMO Sells Shares for Tax Obligations

NeuroPace Inc.'s Chief Medical Officer, Martha Morrell, disposed of 357 shares of common stock at $8.88 per share to cover tax withholdings from a restricted stock unit award vesting.

Summary

• Martha Morrell, Chief Medical Officer of NeuroPace Inc., disposed of 357 shares of common stock.
• The transaction occurred on August 27, 2025, at a price of $8.88 per share.
• These shares were withheld by NeuroPace Inc. to satisfy tax withholding obligations related to the vesting of a restricted stock unit (RSU) award.
• Following this transaction, Ms. Morrell beneficially owns 84,817 shares of common stock.

Sentiment

Score: 6

Explanation: The transaction itself is neutral as it's a tax-related disposition. However, it stems from the vesting of an RSU award, which is a positive compensation event for the executive, indicating continued alignment with company performance.

Positives

• The transaction indicates the vesting of a restricted stock unit (RSU) award, which is a positive compensation event for the Chief Medical Officer.

Industry Context

This is a routine insider transaction related to executive compensation, common across all industries when restricted stock units vest. It does not reflect any specific industry trends or competitive actions.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction related to executive compensation. It confirms the vesting of an RSU award, which is a standard part of executive incentive plans.
• Employees: The vesting of RSUs and subsequent tax withholding is a common practice in executive compensation, reflecting standard benefits.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction where the Chief Medical Officer disposed of shares to cover tax obligations upon the vesting of restricted stock units. Such transactions are standard compensation events and do not typically indicate a change in management's view of the company's prospects or warrant a change in investment recommendation based solely on this filing. The underlying RSU vesting is a positive for the executive, but the transaction itself is neutral for stock valuation.

Keywords

NeuroPace Inc, NPCE, Martha Morrell, Chief Medical Officer, Form 4, Insider Transaction, Stock Vesting, Tax Withholding, Restricted Stock Unit